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Abstract
Despite being the most effective treatment for Parkinson’s disease, L-DOPA causes a development of dyskinetic movements
in the majority of treated patients. L-DOPA-induced dyskinesia is attributed to a dysregulated dopamine transmission within
the basal ganglia, but serotonergic and noradrenergic systems are believed to play an important modulatory role. In this
study, we have addressed the role of the locus coeruleus nucleus (LC) in a rat model of L-DOPA-induced dyskinesia. Single-
unit extracellular recordings in vivo and behavioural and immunohistochemical approaches were applied in rats rendered
dyskinetic by the destruction of the nigrostriatal dopamine neurons followed by chronic treatment with L-DOPA. The results
showed that L-DOPA treatment reversed the change induced by 6-hydroxydopamine lesions on LC neuronal activity. The
severity of the abnormal involuntary movements induced by L-DOPA correlated with the basal firing parameters of LC
neuronal activity. Systemic administration of the LC-selective noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-
bromobenzylamine did not modify axial, limb, and orolingual dyskinesia, whereas chemical destruction of the LC with
ibotenic acid significantly increased the abnormal involuntary movement scores. These results are the first to demonstrate
altered LC neuronal activity in 6-OHDA lesioned rats treated with L-DOPA, and indicate that an intact noradrenergic system
may limit the severity of this movement disorder.
Citation: Miguelez C, Aristieta A, Cenci MA, Ugedo L (2011) The locus coeruleus Is Directly Implicated in L-DOPA-Induced Dyskinesia in Parkinsonian Rats: An
Electrophysiological and Behavioural Study. PLoS ONE 6(9): e24679. doi:10.1371/journal.pone.0024679
Editor: David I. Finkelstein, The Mental Health Research Institute of Victoria, Australia
Received March 30, 2011; Accepted August 17, 2011; Published September 9, 2011
Copyright:  2011 Miguelez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Ministry of Science and Technology (SAF 2009-08664) and the Basque Government (SAIOTEK SA 2010/00033 and
GIC07/143-IT-201-07). CM has a fellowship from the Basque Government and AA a grant from the University of the Basque Country (UPV/EHU). The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: luisa.ugedo@ehu.es
Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative
process that causes the most common movement disorder of basal
ganglia origin [1]. The motor impairment in PD arises from the
selective loss of dopaminergic neurons in the substantia nigra pars
compacta and the subsequent reduction of dopamine levels in the
striatum [2]. Currently, pharmacological dopamine replacement
with L-DOPA is the gold standard treatment for PD. However,
long-term administration of L-DOPA induces abnormal involun-
tary movements known as L-DOPA-induced dyskinesias (LID).
These motor complications are discomforting and potentially
disabling, and affect up to 40% of PD patients within 5 years of
treatment [3]. There is vast consensus that LID results from
dysregulated dopamine neurotransmission depending on both
presynaptic alterations and post-synaptic dopamine receptor
supersensitivity (reviewed in [4,5,6,7]). However, there is also
evidence implicating the noradrenergic system in LID: (1) L-
DOPA may be transformed into noradrenaline [8], and
radioligand binding data demonstrate that dopamine produced
from L-DOPA and some L-DOPA metabolites bind with high
affinity not only D1 and D2 dopamine receptors, but also to a2A
and a2C-adrenoceptors [9]; (2) post-mortem studies have revealed
a substantial loss of noradrenergic neurons [10,11], a decrease in
noradrenaline levels in the brain [12,13] and reduced levels of the
noradrenaline transporter in several noradrenergic areas in the
brains of PD patients [14]; (3) studies using a2-adrenoceptor
antagonists, such as idazoxan, yohimbine and fipamezole, show a
significant reduction in dyskinesia in 6-hydroxydopamine (6-
OHDA)-lesioned rats [15], 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP)-lesioned primates [16,17,18,19] and PD patients
[20]. Clonidine, an a2-adrenoceptor agonist, also reduces LID in
rodent models and PD patients [15,20]. In addition, a1-
adrenoceptors contribute to L-DOPA-induced hyperactivity in
MPTP-lesioned macaques [21].
The largest population of central noradrenergic neurons is
located in the locus coeruleus (LC), which undergo degeneration in
PD [22]. Under control conditions, a substantial amount of
dopamine is present in the LC [23,24,25], where it is used as a
precursor of noradrenaline or as a neurotransmitter itself.
Dopamine inhibits LC neuronal electrical activity [26,27] but
also stimulates LC cells by acting on a1-adrenoceptors [25].
Recently, we have shown that nigrostriatal degeneration decreases
LC noradrenergic neuronal basal firing rate [28]. Studies
examining the impact of LC lesions on the severity of L-DOPA-
induced dyskinesia have produced conflicting results. In one study
[29], rats with a combined lesion of noradrenergic and
dopaminergic systems expressed more severe LID than rats with
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bined lesions of the dopaminergic and noradrenergic pathways
increased the motor response to L-DOPA [31] but did not modify
motor response alterations induced by chronic L-DOPA treat-
ment, measured as a shortening in the duration of contralateral
rotation [32].
In this study, we have tested the hypothesis that LC neuronal
activity plays an important modulatory role in LID. The study was
performed in 6-OHDA-lesioned rats that were rendered dyskinetic
with a course of daily L-DOPA treatment. In separate exper-
iments, we examined the effects of LC damage on the severity of
LID and we recorded single unit extracellular activities from LC
neurons. Our data demonstrate that chemical local lesions of the
LC increase L-DOPA-induced abnormal involuntary movement
scores, and that these scores are strongly correlated with several
parameters of LC noradrenergic neuronal activity. Taken
together, these results provide both electrophysiological and
behavioural support to an involvement of the LC in the
development of LID.
Materials and Methods
Subjects
Female Sprague-Dawley rats (220–225 g) were housed under a
12:12 h light:dark cycle with food and water provided ad libitum.
Every effort was made to minimise animal suffering and to use the
minimum number of animals possible. Experimental protocols
were reviewed and approved by the Local Ethical Committee for
Animal Research at the University of the Basque Country and
Lund University. All of the experiments were performed in
compliance with the European Community Council Directive on
‘‘The Protection of Animals Used for Experimental and Other
Scientific Purposes’’ (86/609/EEC) and with Spanish Law (RD
1201/2005) for the care and use of laboratory animals.
Experimental design and groups
As it is illustrated in Figure 1, this study was composed of three
different experiments.
Experiment 1. 6-OHDA-lesioned and control animals were
treated chronically with either L-DOPA or saline. In all groups,
the electrophysiological characteristics of LC neurons were
analysed 24 h after the last dose of the corresponding drug. The
groups included in this experiment are referred to as sham saline
(n=8), sham L-DOPA (n=7), 6-OHDA saline (n=9) and 6-
OHDA L-DOPA (dyskinetic or non-dyskinetic, n=8 and 3,
respectively).
Experiment 2. DSP-4 or saline was injected in 6-OHDA-
lesioned and control animals. Two weeks later, animals were
chronically treated with L-DOPA or saline, and abnormal
involuntary movements (AIMs) were monitored. The different
groups of animals included in this study were 6-OHDA (n=10), 6-
OHDA+DSP-4 (n=10), DSP-4 (n=6) or sham animals (n=5).
Experiment 3. In eight dyskinetic animals, ibotenic acid was
injected into the right LC to destroy the noradrenergic nucleus on
day 31st after the beginning of L-DOPA chronic treatment. Five
days after LC lesion, AIMs were evaluated for another 32 days in
10 additional testing sessions. The severity of LID before and after
the LC lesion was compared. In five additional dyskinetic animals,
a vehicle injection (Dulbecco’s buffered saline solution) was
performed in the right LC on day 31
st and the same protocol as
the one used for the LC-lesion group was used. This sham group
was introduced in order to exclude an effect of the surgery on the
expression of dyskinesia.
Neurotoxic lesions
6-Hydroxydopamine lesion. At the beginning of the study,
6-hydroxydopamine (6-OHDA-HCl; Sigma-Aldrich) was injected
into the right median forebrain bundle (MFB) according to our
established procedures [33]. 6-OHDA is a neurotoxin commonly
used to lesion dopaminergic pathways and generate experimental
models for Parkinson disease. Briefly, rats were anesthetized with
isofluorane and mounted on a Kopf stereotaxic frame, two
injections of 7.5 and 6 mg 6-OHDA (free-base) were then
performed at two coordinates at a rate of 0.5 ml/min. In order
to project noradrenergic fibres, thirty minutes before lesioning,
desipramine (25 mg/kg, i.p.) was administered.
DSP4 administration. Saline or N-(2-chloroethyl)-N-ethyl-
2-bromobenzylamine (DSP-4) (50 mg/kg, i.p.) was administered
to 6-OHDA-lesioned or sham animals. In both groups, citalopram
(20 mg/kg, i.p.) was also administered. DSP-4 exerts neurotoxic
actions on noradrenergic neurons and selectively damages
noradrenergic projections originating from the LC. DSP-4
solution was made fresh and placed in an opaque, tightly sealed
container due to its instability and light sensitivity as described in
[34].
LC lesioning with ibotenic acid. Animals were
anaesthetised with isofluorane and mounted in a stereotaxic
frame. The head was oriented at 15u to the horizontal plane (nose
down), and 1 ml of ibotenic acid (2 mg/ml) or vehicle was injected
into the right LC, AP: -3.7 mm, ML: +1.1 mm, DV: -5.5 relative
to lambda [35]. The toxin was infused at a rate of 0.5 ml per min,
and the needle was left in place for another 2 minutes before being
slowly retracted.
Behavioural Tests
Amphetamine-induced rotation. Two weeks after the
lesion with 6-OHDA, animals were injected with 2.5 mg/kg D-
amphetamine to screen for the severity of the dopaminergic lesion.
Ipsilateral rotations were induced and recorded for 90 min. Only
rats rotating more than five full turns per minute, corresponding to
a .90% striatal DA depletion [36,37], were included in the study.
Sham animals also received the same dose of D-amphetamine.
Cylinder test. Forelimb use asymmetry was measured using
the cylinder test, as described previously [38]. Rats were placed
individually in a 20-cm diameter glass cylinder and allowed to
move freely. Each animal was left in place until it performed at
least 20 supporting paw placements on the walls of the cylinder.
To obtain an index of forelimb use asymmetry, the following
formula was used: [contralateral paw placements/(ipsilateral +
contralateral paw placements)] 6100. In each study, the cut-off
asymmetry score indicative of severe dopaminergic damage was
obtained by subtracting 3 standard deviations from the mean
value measured in intact rats (corresponded to a 99.73%
confidence limit).
Abnormal involuntary movement rating. AIMs were
induced in 6-OHDA-lesioned rats by chronic daily injections of
L-DOPA (6 mg/kg, s.c., in combination with the peripheral
decarboxylase inhibitor benserazide, 12 mg/kg, s.c.) over 3 weeks.
The development of L-DOPA-induced AIMs was monitored and
scored according to a rat dyskinesia scale described extensively in
[39]. When a plateau was reached, the daily L-DOPA treatment
was changed to a maintenance dose of twice-weekly
administration [40,41]. On the testing days, rats were placed
individually in transparent empty plastic cages for at least 10
minutes prior to drug administration. Following the L-DOPA
injection, each rat was observed for one minute every 20
th minute
for 3 hours. Three subtypes of dyskinetic movements (axial, limb
and orolingual AIMs) and asymmetric locomotive behaviour
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described in [33] where each item is rated on a scale from 0 to 4
based on the proportion of observation time during which it is
present. In addition, the amplitude of axial and limb AIMs was
rated on a scale from 0 to 4 as first described in [37]. Axial, limb,
and orolingual AIMs were analysed separately from locomotive
AIMs using the following parameters: Sum AIMs, sum of axial,
limb and orolingual AIM scores (basic scale) for an entire testing
session; Global AIMs: for each AIM subtype, the basic severity score
was multiplied with the amplitude score on each monitoring
period, and all these products were summed for each testing
session [42,43]. The Time-course of AIMs after an L-DOPA injection
was expressed by the ‘‘area under the curve’’ (AUC) of the Sum
AIMs parameter. L-DOPA-treated rats were classified as
‘‘dyskinetic’’ or ‘‘non-dyskinetic’’ prior to the electrophysiological
experiments. The ‘‘non-dyskinetic’’ group included animals that
either developed mild or no AIMs (basic severity grade 0–1 on
each AIM subtype), whereas rats classified as ‘‘dyskinetic’’ showed
moderate to severe AIMs (basic severity grade of $2 on at least
two of the three AIM subtypes) [42].
Electrophysiological procedures
Single-unit extracellular recordings of LC neurons were
performed as detailed in [44]. Animals were anaesthetised with
chloral hydrate (400 mg/kg, i.p.). The rat was placed in a
stereotaxic frame, and the body temperature was maintained at
,37uC for the entire experiment. The head was oriented at 15u to
the horizontal plane (nose down), and the recording electrode
(filled with a 2% solution of Pontamine Sky Blue in 0.5% sodium
acetate) was lowered into the right LC (relative to lambda: AP:
-3.7 mm, ML: +1.1 mm, DV: -5.5 to -6.5 mm). LC neurons were
identified by standard criteria that included the following
characteristics: 1) spontaneous activity displaying a regular rhythm
and a firing rate between 0.5–5 Hz (Figure 2A); 2) characteristic
spikes with a long-lasting, positive-negative waveform (Figure 2B);
and 3) a biphasic excitation-inhibition response to pressure applied
to the contralateral hind paw (paw pinch). Burst-firing onset and
offset was defined as the concurrence of two spikes with an
interspike interval between 0.08 and 0.16 s, respectively
[45,46,47].
Firing patters were analysed offline using the computer software
Spike2, and the following parameters were calculated: firing rate,
coefficient of variation (percentage ratio of standard deviation to
the mean interval value of an interspike time-interval histogram),
the percentage of spikes in burst and the percentage of cells
exhibiting burst firing. The number of spontaneously active
noradrenergic neurons was determined in 10 stereotaxic electrode
tracks first 100 mm concentrically around the first track (9 tracks)
and then 200 mm rostral to the initial track (1 track). When one
track was not passing through the LC, an additional track rostral
to the initial one was performed. The pattern was constant for all
animals. Posterior verification of the recording site confirmed that
all the recorded neurons belonged to the LC (Figure 2C).
At the end of each experiment, a Pontamine Sky Blue mark was
deposited at the recording site by passing a 5 mA cathodic current
for 10 minutes through the recording electrode. Animals were
deeply anaesthetised and transcardially perfused with 4% ice-cold
buffered paraformaldehyde prepared in 0.1 M phosphate buffer.
Brains were removed and transferred to a 25% sucrose solution
until they sank. The brains were cut in coronal 40-mm sections using
a freezing microtome (HM 430, Microm), and slices were conserved
in cryoprotective solutions at 220uC until further processing.
Figure 1. Experimental design. Experiment 1: At the beginning of the study, animals were lesioned with 6-OHDA injected into the right MFB.
Two weeks later, the severity of the lesion was screened by forelimb use on a cylinder and amphetamine-induced rotations. To develop stable AIMs,
rats were injected daily with 6 mg/kg L-DOPA (plus 12 mg/kg benserazide) or saline for 21 days, and AIMs were rated 2-3 days per week. At the end of
the chronic treatment, L-DOPA was administered twice per week, and electrophysiological experiments were performed. Experiment 2: Animals were
lesioned with 6-OHDA injected into the right MFB, and the severity of the lesion was screened in the 4
th week. DSP-4 (50 mg/kg, i.p.) was
administered to some groups to induce an additional noradrenergic lesion. Between the 6
th and 9
th weeks, animals were treated daily with L-DOPA (6
mg/kg plus 12 mg/kg benserazide, s.c.) or saline, and AIMs were monitored 2-3 times per week. Experiment 3: Animals were lesioned, screened and
AIMs were induced and evaluated. The severity of the AIMs was maintained by administering L-DOPA twice per week. On day 30 after the 6-OHDA
lesion, dyskinetic animals were injected with ibotenic acid or vehicle into the right LC. Five days after noradrenergic damage, AIMs were evaluated
regularly for four weeks. At the end of each study, all animals were transcardially perfused, and the brains were extracted, cut and stored for
subsequent histological verification or immunohistochemical procedures.
doi:10.1371/journal.pone.0024679.g001
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Tyrosine hydroxylase and Dopamine-b-hydroxylase immu-
nohistochemistry. Tyrosine hydroxylase (TH)-immunostaining
was used to examine the degree of dopamine denervation in the
striatum. The precision of this method to quantify the degree of the
lesion is confirmed by the linear relationship between the number of
immunoreactive neurons in the substantia nigra pars compacta and
the optical density in the striatum [48]. Dopamine-b-hydroxylase
(DBH)-immunostaining was utilised to evaluate the depletion of the
LC noradrenergic projections to the prefrontal cortex as an index of
the efficacy of DSP-4 treatment.
For TH-immunostaining, after inactivation of endogenous
peroxidases (3% H2O2 and 10% methanol in potassium-
phosphate buffered saline (KPBS) for 30 min), sections were pre-
incubated for 1 h in 5% normal goat serum +0.25% Triton X-100
in KPBS. The primary antibody used for the detection of TH
(rabbit anti-TH, Pel-Freez Biologicals, P40101-O) was diluted
1:1000, and sections were incubated for 36 h at 4uC. Subsequent-
ly, the sections were treated with a biotinylated goat antibody
against rabbit IgG (BA 1000, Vector Laboratories, Burlingame,
CA, USA) diluted 1:200, and sections were incubated for 2 h.
Both immunoreagents were diluted in 5% or 2.5% normal goat
serum (for the primary and secondary antibodies, respectively)
+0.5% Triton X-100. Thereafter, sections were incubated with an
avidin–biotin–peroxidase complex (ABC kit, PK-6100, Vector
Laboratories, 1 h). Finally, the peroxidase reaction was developed
with 3,39-diaminobenzidine and 0.03 % H2O2. Sections were
rinsed, mounted onto gelatin-coated slides, dehydrated, cleared
with xylene and coverslipped.
For DBH-immunostaining, a similar protocol was followed. In
this case, a mouse anti-DBH monoclonal antibody 1:1000
(Chemicon International, Temecula, CA 92590 USA) and a
biotinylated horse anti-mouse antibody 1:200 (BA 2001, Vector
Laboratories, Burlingame, CA, USA; diluted in normal horse
serum) were used.
Thionine and neutral red staining. To verify the lesion with
ibotenic acid, thionine staining on brain sections containing the LC
was performed. Slices were rinsed once, mounted on glass slides and
processed asfollows: distilled water (265 min),70% ethanol (10 min),
96% ethanol (2 min), 96% ethanol/10% paraformaldehyde (4/1,
5 min), 96% ethanol (2 min), chloroform/ethyl ether/96% alcohol
(8/1/1, 10 min), 96% ethanol (2 min), 100% ethanol (262m i n ) ,
xylene (5 min) and 100% ethanol (262 min), 96%, ethanol (2 min),
96% ethanol (10 min), 70% ethanol (5 min), 50% ethanol (5 min),
thionine (1 g/100 ml, 20–45 min), distilled water (1 min), distilled
water/glacial acetic acid, (1000/3, 1 min and 30 sec), 70% alcohol/
glacial acetic acid (1000/3, 1 min and 30 sec), 96% ethanol (2 min),
100% ethanol (2 min), xylene (268 min)]. Immediately after the
staining the glasses were coverslipped.
For the location of the recording site (Figure 2B), brain sections
containing the LC were rinsed 3610 min before being mounted
on gelatinised glass slides and processed as follows: 1% neutral red
(10 min), distilled water (2 rinses), 70% ethanol (20 sec), 95%
ethanol (20 sec), 100% ethanol (30 sec) and xylene (2 min).
Afterwards, glasses were coverslipped and examined microscop-
ically. Only cells recorded within the LC were included in this
study.
Optical density or cell counting. For TH- and DBH-
immunostaining, three sections containing striatum or prefrontal
cortex, respectively, were first captured using a digital camera and
mean optical density was visualized using image analysis NIH-
produced software, ImageJ (http://rsb.info.nih.gov/nih.image/
default.html). Images from control and treated groups were
processed under the same light and contrast conditions and
identical camera setting were used to capture them. For TH-
immunostaining, the whole striatum was delineated and its optical
density was expressed as a percentage of that on the contralateral
intact side after background subtraction (background was measured
in the cortex on the side ipsilateral to the lesion). Densitometric
analysis of DBH-immunoreactivity was performed only in the
prefrontal cortex (bregma +2.70 mm) because the signal from the
striatum was very close to background levels. Two sample areas per
section were analyzed. The DBH optical density levels were
expressed as a percentage of the values from intact controls.
For verifying LC lesion after ibotenic acid injection, morpho-
logical and stereological approaches were used. First, as detailed in
[48,49,50], neuronal loss and glial reactions were evaluated using a
light microscope (Nikon Optiphot, x10 objective). Second,
stereological cell counting was performed in 5 to 10 regularly
spaced sections along the LC by the optical dissector method using
the Mercator image analysis system (Explora Nova, France) as
described in [28].
Drugs
The drugs used in this study were L-DOPA (L-3,4-dihydroxy-
phenylalanine methyl ester hydrochloride), benserazide-HCl,
Figure 2. Electrophysiological and histological verification of LC neuron recordings. Example of raw trace of recorded action potentials
(A). Scale-up of single spike from LC neuron recorded in vivo (B). Pictures were taken from Spike2 recordings. Histological verification of the recording
site in the LC (C). Abbrev: LC, locus coeruleus; 4V, 4th ventricle; Me5, mesencephalic trigeminal nucleus.
doi:10.1371/journal.pone.0024679.g002
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phate, ibotenic acid (a-amino-3-hydroxy-5-isoxazoleacetic acid)
and DSP-4 (N-(2-Chloroethyl)-N-ethyl-2- bromobenzylamine
hydrochloride) (Sigma-Aldrich Co, St Louis, USA). Chloral
hydrate, desipramine, L-DOPA, benserazide, DSP-4 and amphet-
amine were prepared in 0.9% saline; 6-OHDA was prepared in
distilled water containing 0.2 mg/ml ascorbate. Ibotenic acid was
dissolved in Dulbecco’s buffered saline solution containing (in
mM): NaCl 136.9, KCl 2.7, NaH2PO4 8.1, KH2PO4 1.5, MgCl2
0.5 and CaCl2 0.9 (pH 7.4). Except for chloral hydrate, drugs were
prepared on the day of the experiment.
Statistical analysis of data
Experimental data were analysed using the computer program
GraphPad Prism (v. 5.01, GraphPad Software, Inc). The
electrophysiological data were analysed by one-way analysis of
variance (ANOVA) or Fisher’s exact test for a comparison of the
number of cells with burst-firing activity. Comparisons of AIMs
scores were carried out using one- or two-way ANOVA. The AUC
of AIMs after a single dose of L-DOPA was analysed using a one-
way ANOVA comparing several groups. When the evolution of
AIMs after LC lesion with ibotenic acid was evaluated, repeated
measures two-way ANOVA was utilised. All significant ANOVAs
were followed by post-hoc comparisons using the Bonferronis or
Dunnett’s test. Linear regression analyses were used to assess
correlations between electrophysiological and behavioural data.
The level of statistical significance was set at p,0.05. Data are
presented as group means 6 standard error of the mean (S.E.M.).
Results
Development of L-DOPA-induced abnormal involuntary
movements
Chronic L-DOPA administration (6 mg/kg plus benserazide
12 mg/kg) led to a rapid onset of AIMs in the majority of the 6-
OHDA-lesioned rats (8/11 in experiment 1). Axial, limb and
orolingual AIM scores increased during the first week of treatment
and reached a plateau by the second week (Figure 3A).
Locomotive AIMs also increased over the time, but showed larger
variability between animals and testing sessions (Figure 3B). Sham
animals treated with L-DOPA or saline, and 6-OHDA-lesioned
animals treated with saline did not develop any abnormal
movements.
The time course of the AIMs after a single injection of L-DOPA
showed the expected profile (Figure 3C and D). The first signs of
dyskinesia were evident 10–20 min after the injection, the peak
severity occurred at 40–80 min, and all AIMs subsided by 140–
160 min.
Basal electrophysiological activity in the LC in control
and 6-OHDA-lesioned rats following saline or L-DOPA
treatment
Three hundred forty-eight noradrenergic neurons were record-
ed in the LC: 79 neurons from the sham saline group (n=8
animals), 70 neurons from the sham L-DOPA group (n=7), 90
neurons from the 6-OHDA saline group (n=9) and 109 neurons
from the 6-OHDA L-DOPA group (n=12). In the latter group, 77
neurons were recorded from dyskinetic animals (n=8) and 32
from non-dyskinetic animals (n=3). Neurons were recorded 24 h
after the last injection of saline or L-DOPA. All cells exhibited the
typical electrophysiological characteristics of noradrenergic neu-
rons (see ‘‘Electrophysiological procedures’’) and were localised
within the LC.
Neuronal basal firing rate significantly varied between groups
(F(4,346)=12.11, p,0.001, one-way ANOVA) (Table 1). Consistent
with previous results [28], neurons recorded from the 6-OHDA-
lesioned group showed a significantly lower basal firing rate
compared to neurons from control animals when treated with
saline (p,0.05, Bonferroni’s post-hoc test). After chronic treat-
ment with L-DOPA, neuronal basal firing rate was similar to
control values in dyskinetic animals, but non-dyskinetic animals (6-
OHDA lesioned treated with L-DOPA) did not differ from 6-
OHDA-lesioned animals treated with saline. Significant differenc-
es were also found on the coefficient of variation (F(4,341)=6.95,
p,0.0001, one-way ANOVA, Table 1). In 6-OHDA lesioned
animals treated with L-DOPA, dyskinetic animals had a higher
CV value than 6-OHDA lesioned animals treated with saline
(p,0.01, Bonferroni post hoc test) but was similar to values
obtained in the sham groups. 6-OHDA lesioned animals treated
with saline or with L-DOPA (non dyskinetic) showed similar CV
values. The latter group had also significantly lower values that
those in the sham group (p,0.01, Bonferroni post hoc test). The
percentage of neurons with burst-firing activity was significantly
reduced by the 6-OHDA lesion (p,0.05 vs. sham saline, Fisher’s
test, Table 1). Following treatment with L-DOPA, this percentage
increased significantly in dyskinetic animals but remained largely
reduced in the non-dyskinetic cases, which did not differ
significantly from the 6-OHDA saline-treated group. All other
electrophysiological properties, including the percentage of spikes
occurring in burst, the number of active cells per track and the
mean number of spikes per burst, were similar in all groups.
Correlation between the severity of dyskinesia and locus
coeruleus basal neuronal activity
As summarised in Figure 4, regression analyses showed a
significant correlation between L-DOPA-induced dyskinesia and
both basal firing rate and the coefficient of variation values of LC
neurons obtained from each rat. The electrophysiological
parameters were obtained 24 h after the last injection of saline
or L-DOPA and compared with the AIM score from the last
testing session. The sum of axial, limb, and orolingual AIM scores
was positively correlated with the analysed parameters. Each
subtype of dyskinesia (axial, limb and orolingual), analysed
separately, showed significant correlations as well (Figure 4).
Identical results were obtained using global AIMs scores (basic
scores6amplitude scores) (data not shown). Locomotive AIM did
not show any significant correlation with any electrophysiological
characteristic of the LC neurons (Figure 4).
Lack of effect of DSP-4 pretreatment on the
development of L-DOPA-induced abnormal involuntary
movements
In experiment 2 (cf. Figure 1), 6-OHDA-lesioned animals
showing a motor behaviour compatible with a severe unilateral
dopamine loss (screened with the cylinder test and amphetamine-
induced rotations) received DSP-4 or vehicle injection. DSP-4
would affect retrogradely LC cells by specific degeneration of the
noradrenergic nerve terminals. Two weeks later, L-DOPA was
administered daily for three weeks until stable dyskinesia scores
were achieved.
The chronic administration of L-DOPA induced AIMs
exclusively in the DSP4+6-OHDA and 6-OHDA groups. Sham,
DSP-4 or saline-injected animals did not show any dyskinetic
behaviour. Among the groups that developed AIMs, no differences
were observed on either the sum of AIMs or the global AIM scores
(p.0.05, repeated measures two-way ANOVA) (Figures 5A and C)
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(between subjects: F(3,54)=8.31, p,0.001, for group and
F(1,54)=20.71, p,0.001, for treatment; within subjects
F(6,324)=5.46 for time, p,0.001, repeated measures two-way
ANOVA) (Figure 5B). These occurred on the 4
th and 7
th day of L-
DOPA treatment (corresponding to the 2
nd and 3
rd testing
sessions), on which DSP4+6-OHDA lesioned rats showed larger
locomotive AIMs than did the group with 6-OHDA lesions only
(p,0.01 on each day, one-way ANOVA followed by Dunnett’s
post-hoc test).
The AIMs time course following a single dose of L-DOPA was
similar among the dyskinetic groups (AUC, 588 and 715 for the
DSP4+6-OHDA and 6-OHDA-only group, respectively, on the
last testing session; p.0.05, one-way ANOVA) (Figure 5D). The
asymmetric locomotive behaviour tended to be more prolonged in
the double-lesion animals (Fig 5E), although the AUC value did
not differ significantly between these two groups (AUC, 94 and 68
for the DSP4+6-OHDA and 6-OHDA-only group, respectively,
p.0.05, one-way ANOVA).
Impact of locus coeruleus lesioning on L-DOPA-induced
abnormal involuntary movements
To study the impact of a LC lesion in dyskinetic animals,
ibotenic acid or vehicle was injected in the LC on the side
ipsilateral to the 6-OHDA lesion in L-DOPA-treated rats that had
developed stable AIMs (Figure 6; cf. Experimental design in Fig. 1).
Before the LC lesion, the development of dyskinetic movements
(axial, limb and orolingual) on the course of the chronic treatment
was similar in the LC-lesion and sham groups (F(1,99)=0.16,
p.0.05, repeated measures two way ANOVA). Following the LC
lesion, the sum of axial, limb and orolingual AIM score was
significantly different in the LC-lesion group compared to the
sham animals (F(1,99)=8.31, p,0.001, repeated measures two way
ANOVA) for all testing sessions (statistical details in the graph)
Figure 3. Abnormal involuntary movements induced by chronic treatment with L-DOPA in 6-OHDA-lesioned animals. Time course of
changes in dyskinesia evaluated from the sum AIM scores of axial, limb and orolingual (A) or locomotive (B) during L-DOPA (6 mg/kg plus benserazide
12 mg/kg, s.c.) chronic treatment. Time course of sum AIM scores of axial, limb and orolingual (C) or locomotive (D) evaluated after a single injection
of L-DOPA the last testing session (21
st day); n=20, 13, 10 and 10 for 6-OHDA L-DOPA, 6-OHDA saline, sham L-DOPA and sham saline, respectively.
Note that the sham L-DOPA, sham saline and 6-OHDA saline groups did not develop any abnormal movements.
doi:10.1371/journal.pone.0024679.g003
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throughout all testing sessions (10 session post-LC lesion during
32 additional days). Identical results were obtained when the
global AIMs score was used (data not shown). Asymmetric
locomotive behaviour significantly increased during the chronic
treatment in a similar way in both groups (F(1,99)=1.37, p.0.05,
repeated measures two way ANOVA). No differences were
observed after the LC lesion in any group (F(1,99)=2.34, p.0.05,
repeated measures two way ANOVA) (Figure 6B).
As illustrated in Figure 6C, in the LC-lesion group the peak-
severity of the AIMs following a single administration of L-DOPA
was similar before and after the LC lesion. However, the time
course of the AIMs was significantly prolonged after the LC lesion.
Accordingly, AUC values increased significantly on every testing
session after the LC lesion compared to the last day prior to the
lesion (day 30
th on L-DOPA treatment) (F(11,77)=9.52, p,0.001,
repeated measures ANOVA followed by Dunnett’s post-hoc test).
Similar results were obtained in the analysis of the global AIM
scores (data not shown). On the locomotive scores, no differences
were observed after the LC lesion compared with the last day
before the lesion (Figure 6D).
In the LC-lesioned group when analysed separately, axial, limb
and orolingual AIMs were all significantly aggravated by the LC
lesion when compared to the last testing session prior to the LC
lesion (F(19,133)=6.76 for axial, F(19,133)=24.68 for limb and
F(19,133)=17.98 for orolingual AIMs, p,0.001 for all cases,
Table 1. Control and 6-OHDA lesioned animals.
sham 6-OHDA lesioned
Saline L-DOPA Saline L-DOPA (dyskinetic) L-DOPA (non-dyskinetic)
Basal Firing Rate (Hz) 1.9360.10 (79) 2.116 0.10 (70) 1.4760.07 (90)** 2.1060.11 (77)&&& 1.3160.13 (32)###
Coefficient of variation (%) 3861( 7 9 ) 3 7 61( 6 9 ) 3 6 61( 8 7 ) 4 2 61 (76)&& 3062( 3 1 ) ##
% spikes in burst 2.5360.50 (38) 2.4660.51 (37) 3.3960.73 (28) 3.1960.84 (45) 5.7462.32 (5)
Mean spikes/burst 2.0260.03 (38) 2.0860.05 (37) 2.0460.04 (28) 2.0260.02 (45) 2.0060.00 (3)
Neurons with burst firing (%) 48% (38/79) 52% (37/70) 31% (28/90)* 58% (46/77)&&& 16% (5/32)###
Active cells per track 4.0560.48 (8) 3.6860.23 (4)
Rats were treated daily with saline or L-DOPA 6 mg/kg in combination with benserazide 12 mg/kg, s.c. for at least 21 days. All neurons were recorded 24 h after the last
injection of saline or L-DOPA. Each value represents the mean 6 SEM of (n) neurons. Each cell was recorded for 180 seconds. Number of animals included was n=8, 7, 9,
8 and 3 for sham saline, sham L-DOPA, 6-OHDA saline, 6-OHDA L-DOPA (dyskinetic) and 6-ODA L-DOPA (non-dyskinetic), respectively. The parameter ‘‘Active neurons
per track’’ was measured in 10 consecutive tracks of 8 and 4 animals in each group;
* p,0.05 and ** p,0.01 vs sham saline,
## p,0.01 and ### p,0.001 vs. sham L-DOPA,
&& p,0.01 and &&& p,0.001 vs. lesion saline (one-way ANOVA followed by Bonferroni post-hoc test or Fisher’s test for ‘‘Neurons with burst-firing’’).
doi:10.1371/journal.pone.0024679.t001
Figure 4. Regression analysis of the severity of dyskinesia and the electrophysiological parameters of locus coeruleus neurons in
dyskinetic animals. The electrophysiological parameters of LC neurons are represented on the abscissa and the sum AIMs on the ordinate axis. The
basal firing rate was correlated with the sum AIMs (A), and the axial (B), limb (C) and orolingual (D) subtypes. The coefficient of variation also
correlated with the sum AIMs (F) and the axial (G), limb (H) and orolingual (I) subtypes. Locomotive behaviour was not correlated with the basal firing
rate (E) or with the coefficient of variation in the LC (J). Each symbol represents an animal. Only 6-OHDA lesioned animals treated with L-DOPA (8
dyskinetic and 3 non-dyskinetic) are included in the analysis.
doi:10.1371/journal.pone.0024679.g004
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(Figures 6E, F, and G).
Verification of the lesions
All 6-OHDA-lesioned animals included in the study showed
.95% reduction in TH-fibre density in the striatum on the side
ipsilateral to the lesion (Figures 5F, upper boxes). DBH-
immunostaining revealed a reduction of noradrenergic fibers
.79% in the prefrontal cortex in all animals sustaining an
intraperitonal injection of DSP-4 (Figures 5F, bottom boxes).
LC lesions produced by local injection of ibotenic acid were
verified first by microscopic analysis showing loss of large LC
neuron morphology and glial reaction on the lesion side compared
to the intact side (Figure 6H). No damage of the surrounding areas
was detected. Additional quantification of LC cell bodies by
stereological methods showed a mean reduction of 4264% on the
lesion side in all the dyskinetic animals included in the experiment.
Discussion
The present data constitute the first combined electrophysio-
logical and behavioural study that implicates the LC in L-DOPA-
induced dyskinesia. Our results reveal a strong correlation between
basic parameters of LC neuronal activity and dyskinesia severity,
and moreover show that neuronal damage in this structure
increases the L-DOPA-induced AIM scores by prolonging
dyskinesia duration.
Significance of the electrophysiological findings
Similar to the effects observed in some basal ganglia nuclei
[51,52], chronic L-DOPA administration induced changes in the
basal electrophysiological properties of LC noradrenergic neurons.
We have reproduced our previous results [28] and observed that,
in the dopamine-depleted condition, the basal firing rate and the
number of neurons with burst-firing in LC cells were significantly
decreased. In addition, interesting differences were obtained in the
group of 6-OHDA-lesioned animals treated with L-DOPA. LC
neurons in dyskinetic animals had a more irregular firing pattern
and a higher firing rate, and the number of neurons showing burst-
firing activity was larger compared to those that did not developed
dyskinesia. Surprisingly, LC neurons in dyskinetic animals
displayed electrophysiological characteristics similar to control
animals, but 6-OHDA-lesioned animals that did not developed
dyskinesia remained similar to 6-OHDA-lesioned rats treated with
saline. These data suggest a recovery of the electrophysiological
properties towards the control state in dyskinetic rats. The
observed difference between dyskinetic and non-dyskinetic animals
may depend on a larger brain exposure to L-DOPA and
dopamine in the former group. Indeed, LID is associated with
increased striatal concentrations of dopamine [42,52,53] or L-
DOPA [36,52]. The observed changes cannot be attributed to a
direct action of L-DOPA-derived neurotransmitters on adrenergic
and dopaminergic receptors because 24 h after the injection, no L-
DOPA-derived neurotransmitters are present in the brain
[36,52,54]. However, it is likely that the daily administration of
Figure 5. Abnormal movements induced by the chronic treatment with L-DOPA in animals lesioned with 6-OHDA or DSP-4+6-
OHDA. The time course of changes in dyskinesia evaluated from the sum (A), locomotive (B) or the global AIM score (C) induced by a 21-day
treatment with L-DOPA (6 mg/kg plus benserazide 12 mg/kg, s.c.). Sum and locomotive AIM score was evaluated every testing session and global AIM
score weekly. Time course of sum AIM scores of axial, limb and orolingual (D) or locomotive (E) evaluated after a single injection of L-DOPA the last
testing session (21
st day). Only groups receiving L-DOPA are included in the graph (n=10, 10, 6 and 5 for DSP4+6-OHDA, 6-OHDA, DSP4 and sham,
respectively). Saline-treated animals, sham L-DOPA and DSP4 groups did not show any sign of dyskinesia. Tyrosine hydroxylase immunostaining in
the striatum of sham and 6-OHDA-lesioned animals (F, upper boxes, scale bar 1 mm). Dopamine-b-hydroxylase immunostaining of sham and DSP-4-
treated animals in the prefrontal cortex (F, bottom boxes, scale bar 200 mm). **p,0.01 vs 6-OHDA (one-way ANOVA followed by Bonferroni post-hoc
test).
doi:10.1371/journal.pone.0024679.g005
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changes that modulate LC neuronal activity. In this sense, a recent
publication [55] have reported that 6-OHDA lesion induces an
increase of a2-adrenoceptor RNA in the LC and that L-DOPA
treatment reverses this increment untill control values. It is well
known that a2-adrenoceptors govern the firing rate in the LC by
inhibiting tonically the neuron activity and that raised levels of
noradrenaline may downregulate these receptors. Thus, it is
bound that our results are directly related to this change in a2-
adrenoceptor expression induced first by the nigrostriatal degen-
eration and later by the chronic treatment with L-DOPA.
The correlation between basic parameter of LC neuronal
activity and dyskinesia severity is a novel, important contribution
of this study. More severe dyskinetic movements had developed in
animals in which LC neurons had a higher basal firing frequency
and coefficient of variation. The latter parameter, which is a
measure of interspike interval regularity, may be indicative of
overall changes in neuronal excitability [56]. In addition, an
increased release of neurotransmitter has been reported to be
associated with burst firing, a form of irregular discharge
[57,58,59]. Voltamperometric experiments also confirm a very
effective transmitter release from the nerve terminal after burst
activation [60]. It is possible that in dyskinetic conditions LC
neurons increased their activity as part of a homeostatic
compensatory response to the prolonged administration of L-
DOPA after dopaminergic loss. In fact, drugs that increase
noradrenergic activity, mainly a2-adrenoceptor antagonists, de-
crease LID not only in rodents [15,38,61,62] but also in primate
models [17,18,63] and humans [20]. However, clonidine also
reduces dyskinesia. To the best of our knowledge, clonidine is the
only a2-adrenoceptor agonist reported to improve dyskinesia. Low
doses of clonidine decrease noradrenergic cell firing through
stimulation of presynaptic a2-adrenoceptors [64]. However, at
higher doses clonidine also increases LC firing rate through a
mechanism involving imidazoline receptors in the LC [65,66]. It is
presently unclear whether a2-adrenoceptor agents modulate LID
by a direct effect on the LC. Importantly, a2-adrenoceptors also
are expressed by striatal output neurons and present in other parts
of the basal ganglia [67,68,69]. Thus, it is possible that treatment
with these drugs improves LID not only by acting on the LC but
also by their broad modulatory actions on the basal ganglia
network.
Effects of LC lesions on the motor response to L-DOPA
Previous studies investigating the effects of LC lesions on L-
DOPA-induced motor complications in 6-OHDA-lesioned rats
have produced some contradictory results. For example, addition-
al noradrenergic denervation with DSP-4 although selectively
increased number of animals that respond to L-DOPA, was
reported not to modify circling behaviour [31], wearing-off type
fluctuations [32], or L-DOPA-induced dyskinesia [70]. In other
studies, the depletion of LC noradrenaline with either DSP-4 or
local 6-OHDA lesions produced a potentiation of parkinsonian-
like symptoms [71,72], an increment of apomorphine-induced
circling behaviour [73], and anticipated the onset and worsened
the severity of L-DOPA-induced AIMs [30]. In the present study,
we used two approaches to investigate the role of LC in dyskinesia.
First, DSP-4 was used to induce the retrograde degeneration of LC
noradrenergic projections. In this experiment, dyskinetic move-
ments that developed in double DSP4/6-OHDA-lesioned rats
were in all respect similar to those seen in 6-OHDA-only animals.
Second, ibotenic acid was used to produce an acute and complete
Figure 6. Involvement of the locus coeruleus in the development of abnormal involuntary movements induced by chronic
treatment with L-DOPA. Briefly, 6-OHDA-lesioned animals were injected daily with L-DOPA (6 mg/kg plus 12 mg/kg benserazide, s.c.) for 21 days
and AIMs were evaluated twice a week. After a 21-day chronic treatment, L-DOPA was administered twice per week. On day 31, animals received an
injection of ibotenic acid or vehicle into the right LC (solid line: LC-lesion group, n=8; dash line: Sham group, n=5), indicated in the graph with an
arrow. Five days after, AIMs were evaluated for another 32 days in 10 additional testing sessions. A significant increase in sum AIM score (A) was
observed in the LC-lesion group. Locomotive AIM remained unaltered after the LC lesion (B). In the LC-lesion group, time course of the L-DOPA-
induced AIMs after a single injection of L-DOPA was significantly prolonged after the LC damage for the sum (C) but not for locomotive AIM score (D).
Bar histograms representing separately axial (E), limb (F) and orolingual AIM scores (G). White or black bars are used for representing each session
before or after the LC-lesion, respectively. Thionine-staining in the LC of 6-OHDA-lesioned animals with an additional LC-lesion (Hi). Dashed squares
are magnified below, corresponding to the LC contralateral (Hii) and ipsilateral to the lesion (Hiii). All slices are 40 mm-thick and were stained using
free-floating slice procedures. Scale bar: 400 mm (Hi) and 200 mm (Hii-Hiii). * p,0.05, ** p,0.01 and *** p,0.001 vs. sham group (repeated measures
two way ANOVA followed by Bonferroni post-hoc test) # p,0.05, ## p,0.01 and ### p,0.001 vs. day 30th (repeated measures ANOVA followed
by Dunnett’s post-hoc test) .
doi:10.1371/journal.pone.0024679.g006
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destroyed once dyskinesia was already established, and the AIM
scores increased significantly after the lesion. DSP-4 is a
neurotoxin highly specific for the nerve terminals originating from
the LC [74,75] whose projections retrogradely degenerate [76].
However, after DSP-4 administration, a slow and gradual recovery
of noradrenaline stores back to control values has been reported
[77,78]. From the electrophysiological point of view, noradrener-
gic depletion with DSP-4 leads to transient electrophysiological
changes in noradrenergic pathways [79,80]. Moreover, mice
whose central noradrenaline levels have been depleted by prior
treatment with DSP-4, the remaining noradrenergic neurons
respond with an increase in noradrenaline turnover after L-DOPA
loading [81]. In the present study, the ascending noradrenergic
fibres were notably affected by the DSP-4 injection. LC-cell bodies
quantification was not performed, however, a recent paper
performed partially in our laboratory, has reported that despite
decreasing cortical noradrenaline levels and affect noradrenergic
neuron terminals, DSP-4 does not affect the functioning of LC
neurons or selectively lesion LC noradrenergic cell bodies [34].
The ability of LC cells to survive the damage from DSP-4 and the
questionable selectivity of the neurotoxin for LC innervation may
be relevant for the understanding of our results. These negative
results are countered by the effects of the ibotenic acid lesion,
resulting in a noticeable increase in dyskinesia duration. These
results are consistent with another study that showed an
aggravation of dyskinetic movements in 6-OHDA-lesioned
animals when the damage to the noradrenergic innervation was
enhanced by omitting desipramine pretreatment prior to the MFB
lesion surgery [30]. Altogether, these results indicate that the role
of the LC in LID may become evident only when an important
degree of degeneration has occurred.
Asymmetric locomotive behaviour was the only abnormal
motor response that did not correlate with LC electrophysiological
properties and did not follow the same increase as the other
abnormal movements after LC destruction. In fact, this behaviour
is not considered a valid measure of dyskinesia because it is
induced by drugs with very low dyskinesiogenic potential, and
because it is not attenuated by compounds that have anti-
dyskinetic efficacy in patients [15,38].
Possible mechanisms by which the LC modulates L-
DOPA-induced dyskinesia
The most recent studies on mechanisms of L-DOPA-induced
dyskinesia have crystallized three main layers of alterations,
namely: (1) presynaptic dysregulation of dopamine release and
clearance; (2) maladaptive molecular and synaptic plasticity in
striatal neurons; (3) changes in firing patterns in the basal ganglia
output nuclei, including the internal segment of the globus pallidus
(GPi), and the substantia nigra pars reticulata (SNpr) (recently
reviewed in [82]). Because of their widespread distribution,
adrenoceptors and noradrenergic projections may potentially
modulate each of the above processes, and the following discussion
will focus only on mechanisms that are supported by sufficient
information. At the presynaptic level, the noradrenergic system
plays an important role in the clearance of L-DOPA-derived
dopamine in 6-OHDA-lesioned rats [54]. Indeed, noradrenergic
fibres can contribute both to the enzymatic breakdown of
dopamine via monoamine oxidase-A (MAO-A) [83,84] and to
dopamine reuptake via the noradrenaline transporter [54]. When
both the noradrenergic and dopaminergic systems are damaged,
L-DOPA-derived dopamine is likely to remain for a longer time in
the brain extracellular space, an effect that would lead to a
prolongation of dyskinesia. A presynaptic mechanism may
therefore explain an increased duration of L-DOPA-induced
AIMs following LC lesion, as observed in the present study. Other
important effects of the noradrenaline system may occur at the
level of the basal ganglia output nuclei. In the rat, the expression of
L-DOPA-induced dyskinesia is associated with distinct neuro-
chemical and electrophysiological changes in the SNpr, consisting
in large elevations of extracellular dopamine and GABA levels
[42,85] accompanied by altered neuronal firing patterns [52]. The
a2-adrenoceptors modulate GABA release in the SNpr [86], and
a1- activation increases the excitability and firing rate in SNpr
neurons [87]. Although low, a noradrenergic reuptake site has also
been observed in the SNpr [88,89]. Interestingly, a recent
publication has revealed that the LC lesion increases the basal
firing rate in the SNpr in 6-OHDA-lesioned rats [73].
Conclusions
The study of the impact of non-dopaminergic systems on the
development of dyskinesia will bring new light to the understand-
ing of PD. In this work, we have demonstrated that the LC
noradrenergic system is involved in the pathophysiology of LID
from both an electrophysiological and a behavioural standpoint.
The modulation of this system may constitute an important
therapeutic approach to the treatment of PD and of the
complications associated with L-DOPA pharmacotherapy.
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